Isocitrate dehydrogenase 1 (IDH1) is mutated in various types of human cancer to IDH1R132H, a structural alteration that leads to catalysis of α-ketoglutarate to the oncometabolite D-2-hydroxyglutarate. In this study, we present evidence that small-mo...

The serine/threonine kinase LKB1 is a well-characterized tumor suppressor that governs diverse cellular processes including growth, polarity and metabolism. Somatic inactivating mutations in LKB1 are observed in about 15-30% of non-small cell lung canc...

The Fas receptor ligand FasL regulates immune cell levels by inducing apoptosis of Fas receptor-positive cells. Here we studied the impact of host FasL on tumor development in mice. Genetically targeting FasL in naive mice increased myeloid cell popula...

Platelet-activating factor receptor (PAFR), a G-protein–coupled receptor, has been implicated in tumorigenesis, but its contributions to metastatic progression have not been investigated. Here, we show that PAFR is overexpressed in non–small cell l...

Restoration of wild-type p53 tumor suppressor function has emerged as an attractive anticancer strategy. Therapeutics targeting the two p53 negative regulators, MDM2 and MDM4, have been developed, but most agents selectively target the ability of only ...